NeuroPace Shares Little Changed After FDA Greenlights AI Device
NeuroPace Inc. shares closed at $16.49, down 0.3%, after the FDA cleared its ECoG Assistant AI tool for epilepsy clinicians. About 105,000 shares traded. The company reported Q1 revenue of $22.1 million and a net loss of $6.7 million. NeuroPace expects FDA review of its Patient Data Management System later in 2026.